ZTS

Zoetis
NYSE

Real-time Quotes | Nasdaq Last Sale

160.97
+0.10
+0.06%
Closed 17:14 09/21 EDT
OPEN
159.34
PREV CLOSE
160.87
HIGH
161.07
LOW
157.42
VOLUME
1.17M
TURNOVER
--
52 WEEK HIGH
165.82
52 WEEK LOW
90.14
MARKET CAP
76.48B
P/E (TTM)
47.61
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
JAZZ vs. ZTS: Which Stock Is the Better Value Option?
JAZZ vs. ZTS: Which Stock Is the Better Value Option?
Zacks · 4d ago
The Argus Dividend Growth Portfolio
Find the latest WEC Energy Group, Inc. (WEC) stock forecast based on top analyst's estimates, plus more investing and trading data from Yahoo Finance
Argus Research · 6d ago
Zoetis Named a Top Company for Working Mothers
For the seventh year in a row, Zoetis has been named one of Working Mother Magazine's 100 Best Companies for Working Mothers.
Business Wire · 6d ago
Weekly Stock List
Find the latest Apple Inc. (AAPL) stock forecast based on top analyst's estimates, plus more investing and trading data from Yahoo Finance
Argus Research · 09/14 01:00
Zoetis is Higher Than Ever Thanks to Pet (and Farm) Spending
As we discussed yesterday, spending on pets hasn't slowed down during the pandemic.According to a survey from TD Ameritrade, 33% of Americans have considered adopting pets because of the pandemic.For dog and cat owners alike, the cost can be higher than expected. Respondents to the survey who owned
InvestorPlace · 09/11 13:04
Zoetis to Participate in the 18th Annual Morgan Stanley Healthcare Conference
Zoetis will present at the 18th Annual Morgan Stanley Healthcare Conference on Wednesday, Sept. 16.
Business Wire · 09/10 13:30
Zoetis: Downgrade To Neutral On Valuation After 37% Gain
Zoetis shares have returned 36.6% since our initial Buy rating in June 2019, outperforming the S&P 500 by approx. 20%. Q2 2020 results showed the resilience of its business during COVID-19, with operational growth of 4% in both revenues and net income. Earnings growth has continued to be driven by the structural drivers of growing pet demand, pricing, new products and operational leverage. Management has revised 2020 guidance upwards, and now expects 3-6% in operational revenue growth and -3% to +1% in EPS growth. With shares at $153.51, we expect the P/E to fall from its current 41x+ to 38.5x, giving an annualised return of only 7.4%. Downgrade to Neutral.
Seekingalpha · 09/09 18:03
Analyst Report: Zoetis Inc.
Find the latest Zoetis Inc. (ZTS) stock forecast based on top analyst's estimates, plus more investing and trading data from Yahoo Finance
Morningstar Research · 09/08 23:04
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Analyst Rating

Based on 20 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ZTS stock price target is 173.36 with a high estimate of 191.00 and a low estimate of 159.00.
EPS
Institutional Holdings
Institutions: 1.14K
Institutional Holdings: 454.38M
% Owned: 95.63%
Shares Outstanding: 475.14M
TypeInstitutionsShares
Increased
367
25.81M
New
116
4.05M
Decreased
391
21.49M
Sold Out
72
2.13M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-1.98%
Pharmaceuticals & Medical Research
-2.24%
Key Executives
Non-Executive Chairman/Independent Director
Michael McCallister
Chief Executive Officer/Director
Kristin Peck
Chief Financial Officer/Executive Vice President
Glenn David
Chief Human Resource Officer/Executive Vice President
Roxanne Lagano
Executive Vice President/General Counsel/Secretary
Heidi Chen
Executive Vice President
Catherine Knupp
Executive Vice President
Roman Trawicki
Independent Director
Paul Bisaro
Independent Director
Frank D'Amelio
Independent Director
Sanjay Khosla
Independent Director
Gregory Norden
Independent Director
Louise Parent
Independent Director
Willie Reed
Independent Director
Linda Rhodes
Independent Director
Robert Scully
Independent Director
William Steere
  • Dividends
  • Splits
  • Insider Activity
Declaration Date
Dividend Per Share
Ex-Div Date
05/20/2020
Dividend USD 0.2
07/16/2020
02/11/2020
Dividend USD 0.2
04/16/2020
12/11/2019
Dividend USD 0.2
01/16/2020
10/03/2019
Dividend USD 0.164
10/21/2019
05/15/2019
Dividend USD 0.164
07/18/2019
02/12/2019
Dividend USD 0.164
04/17/2019
12/12/2018
Dividend USD 0.164
01/17/2019
10/10/2018
Dividend USD 0.126
11/19/2018
05/15/2018
Dividend USD 0.126
07/19/2018
02/13/2018
Dividend USD 0.126
04/19/2018
12/11/2017
Dividend USD 0.126
01/18/2018
10/05/2017
Dividend USD 0.105
11/08/2017
05/22/2017
Dividend USD 0.105
06/13/2017
02/15/2017
Dividend USD 0.105
04/04/2017
12/07/2016
Dividend USD 0.105
01/18/2017
10/06/2016
Dividend USD 0.095
11/01/2016
05/13/2016
Dividend USD 0.095
06/28/2016
02/22/2016
Dividend USD 0.095
04/05/2016
12/18/2015
Dividend USD 0.095
01/19/2016
10/01/2015
Dividend USD 0.083
11/03/2015
07/21/2015
Dividend USD 0.083
08/11/2015
02/27/2015
Dividend USD 0.083
04/07/2015
12/17/2014
Dividend USD 0.083
01/20/2015
10/02/2014
Dividend USD 0.072
11/03/2014
07/31/2014
Dividend USD 0.072
08/18/2014
03/27/2014
Dividend USD 0.072
04/24/2014
12/19/2013
Dividend USD 0.072
01/28/2014
09/13/2013
Dividend USD 0.065
10/30/2013
06/21/2013
Dividend USD 0.065
07/30/2013

Analyst Price Target

The average ZTS stock price target is 173.36 with a high estimate of 191.00 and a low estimate of 159.00.

Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ZTS
Zoetis Inc. is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals. The Company's segments include the United States and International. Within each of these operating segments, it offers a product portfolio for both livestock and companion animal customers. Its livestock products include Ceftiofur injectable line, Draxxin, Spectramast, Bovi-Shield line, Rispoval line, Suvaxyn/Fostera, Embrex devices and Lutalyse. Its companion animal products include Clavamox/Synulox, Convenia, ProHeart, Revolution/Stronghold, Apoquel, Cerenia and Rimadyl.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Zoetis Inc stock information, including NYSE:ZTS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ZTS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ZTS stock methods without spending real money on the virtual paper trading platform.